In addition, the same panel used to assess the sensitivity of cetuximab and dacomitinib in HNSCC cells was used to assess the sensitivity of erlotinib, an EGFR specific small molecule tyrosine kinase inhibitor. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.